<DOC>
	<DOCNO>NCT00955084</DOCNO>
	<brief_summary>The primary objective study allow rollover two remain subject XL999 study continue receive XL999 . The secondary objective study follow : - To evaluate tumor response long term repeat administration XL999 two subject roll XL999 study . - To characterize long term safety tolerability XL999 repeat administration two subject roll XL999 study . - To characterize long term effect XL999 cardiac function repeat administration two subject roll XL999 study .</brief_summary>
	<brief_title>Maintenance Study Long Term Safety XL999</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>The subject currently enrol Protocols XL999001 XL999204 The subject receive XL999 least one year prior enrollment Per respective parent XL999 protocol , subject eligible continue receive XL999 absence progressive disease ( PD ) unacceptable drugrelated toxicity Progressive disease Any development ( ) would meet exclusion criterion subject 's respective XL999 protocol ( XL999001 XL999204 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>